TGTX - שווי פעילות לרווח לפני ריבית, מסים ופחת tgtherapeutics.com

Stable demand for neurology and oncology drugs provides TG Therapeutics, Inc. (TGTX) with a steady cash flow. The EV/EBITDA valuation multiple demonstrates that the current status equals 51.90. Revenues are based on the sale of targeted agents against B-cell neoplasms and multiple sclerosis. The strategy relies exclusively on organic sales growth without engaging in external mergers and acquisitions.

This metric compares the total value of assets and liabilities with cash flow before taxes and depreciation, allowing for an assessment of the business's real value regardless of the debt load. Given the stable US jurisdiction and the humanitarian status of TG Therapeutics, Inc. (TGTX) developments, the enterprise value to EBITDA multiple clearly demonstrates the efficiency of capitalizing biopharmaceutical innovations in the current economic cycle.